An adoptive transfer model of insulin-dependent diabetes mellitus (IDDM) in the nonobese diabetic mouse was used to examine the roles of a4-integrin, vascular cell adhesion molecule 1 (VCAM-1); and intercellular adhesion molecule 1 (ICAM-1) in the pathogenesis of autoimmune diabetes. Antibodies specific for both a4-integrin and one of its ligands, VCAM-1, were able to delay onset of diabetes and decrease the incidence of the disease in adoptive transfer studies. This blocking of disease was accompanied by a marked decrease in lymphocytic infiltration of the islets of Langerhans. Furthermore, these antibodies preferentially block entrance of CD4 T cells into the tissue. Antibodies specific for ICAM-1 had little effect on the onset or incidence of IDDM. Thus, we conclude that an a4-integrin-VCAM-1 interaction is important in T cell entry into the islets of Langerhans and in the pathogenesis of IDDM. In addition, the cascade of events leading to T cell transit across endothelium may be different for CD4 and CD8 cells, and may differ depending on the endothelium involved. Our results support the more general conclusion that an a4-integrin-VCAM-1 interaction may be crucial in allowing activated effector CD4 T cells to leave the blood and enter tissue to clear infection. (J. Clin.
Introduction
The nonobese diabetic (NOD)' mouse spontaneously de- velops autoimmune diabetes and is an animal model for human insulin-dependent diabetes mellitus (IDDM). IDDM is believed to be an autoimmune disease in which activated T lymphocytes destroy the insulin-producing 3-cells of the pancreatic islets ( 1, 2). The islets of Langerhans in normal mice are almost completely devoid of lymphocytes, whereas NOD mice gradually develop insulitis, a mononuclear cell infiltration of the islets consisting mostly of T lymphocytes, before 1 . Abbreviations used in thispaper: EAE, experimental allergic encephalomyelitis; ICAM-1, intercellular adhesion molecule 1; IDDM, insulindependent diabetes mellitus; LFA-1, lymphocyte function-associated antigen 1; NOD, nonobese diabetic; VCAM-1, vascular cell adhesion molecule 1; VLA-4, very late antigen 4. they develop IDDM (3) (4) (5) . IDDM can be adoptively transferred by splenic T cells from diabetic donors and prevented by in vivo T cell depletion (6, 7) . Adoptive transfer experiments using antibody depletion, cell sorting, and transfer of islet-specific cloned T cell lines have demonstrated that both CD4 and CD8 T cells can contribute to the transfer of IDDM (7) (8) (9) (10) .
It has been suggested that macrophages might also be involved in the assault on /3 cells (11, 12) . In fact, adoptive transfer of diabetes in the NOD mouse can be blocked by antibodies against an adhesion-promoting type 3 complement receptor on macrophages which is involved in the migration of macrophages into inflammatory sites ( 13). The administration ofthis antibody prevents intraislet infiltration by both macrophages and T cells. It has been suggested that the receptor on macrophages is involved in allowing these cells to enter the islets, and that blocking entry ofthe macrophages also prevents the entry of T cells.
The mechanism by which the T cells enter islets is still unclear. Recently, our laboratory has shown that surface expression of a4-integrin is required for the entry of activated effector CD4 T cells that transfer experimental allergic encephalomyelitis (EAE) into brain parenchyma ( 14). a4-Integrinhigh, myelin basic protein-specific cloned CD4 T cells can enter the brain parenchyma, whereas a4-integrin-low variants ofthese clones are unable to induce disease or enter brain parenchyma. Furthermore, antibodies to a4-integrin, to one of its ligands, vascular cell adhesion molecule 1 (VCAM-1), and to intercellular adhesion molecule 1 (ICAM-1) each delayed onset ofEAE transferred with these cloned T cells or with polyclonal T cells. On the basis of these studies, we proposed that the elevated level of a4-integrin, or very late antigen 4 (VLA-4), expressed on effector T cells facilitates interaction with VCAM-1, which can be induced on endothelium, allowing activated T cells to leave blood and enter peripheral tissues ( 14).
To test the generality of this result, and to examine the means by which islet-specific T cells enter the islets of Langerhans to cause IDDM, we have here examined the roles of a4-integrin, VCAM (Pharmingen). Fluorescence intensity was measured by FACS. The T cells from newly diabetic NOD mouse spleen express significant levels of both a4-integrin and ICAM-1, but, as would be expected, they do not express VCAM-1 (Fig. 1 ).
The ability ofspleen cells to transfer diabetes can be inhibited with antibodies specific for a4-integrin. To determine whether the a4-integrin seen on the T cells of newly diabetic NOD mice plays a role in the induction of diabetes in vivo, we asked whether antibodies to a4-integrin or to VCAM-1 could influence the adoptive transfer of diabetes in the NOD mouse. Spleen cells were isolated from newly diabetic female NOD mice. One portion of these spleen cells was passed over an anti-mouse Ig column to separate the T cells. These purified T cells were then stained with saturating concentrations of antibodies specific for a4-integrin, ICAM-l, and VCAM-1, as well as isotype-matched control antibodies directed against the mouse CD45 molecule (Fig. 1 ). These anti-CD45 antibodies were used in in vivo experiments to control for depletion of T cells by antibody-mediated mechanisms. The amount of anti-CD45 used stained the NOD T cells -50 times more intensely than either the anti-a4-integrin antibody or the anti-ICAM-1 antibody (Fig. 1 ) . Thus, control antibodies were used in excess. A suitable endothelial cell-specific antibody to serve as a control for anti-VCAM-1 was not available, so no control antibody was used for experiments with anti-VCAM- 1 bind activated endothelial cells and has no effect in these studies, it can serve as a control.
The remaining spleen cells from the newly diabetic NOD mice were used for an in vivo adoptive transfer experiment. The various antibodies were mixed with the spleen cells and incubated at 370C for 30 min. 2 X 107 spleen cells, together with the antibody, were then injected into 7-8-wk-old, irradiated female NOD mice.
Treatment of the cells used in adoptive transfer of diabetes with the antibody against a4-integrin significantly delayed the onset of diabetes and significantly decreased the incidence of disease (Fig. 2) . When antibody to a4-integrin was given once at the time of injection of spleen cells, the onset of IDDM was delayed by 5 d and the incidence of disease was decreased by 25% as compared to mice that received either spleen cells alone or spleen cells plus the isotype-matched control anti-CD45 antibody (Fig. 2 A) . If the animals were injected three additional times with anti-a4-integrin antibody, the onset of diabetes was delayed by 17 d and the incidence of disease was decreased by 90% as compared to the animals given either PBS or four injections of the isotype-matched control anti-CD45 antibody (Fig. 2 B) .
The ability of spleen cells to transfer diabetes can also be inhibited with antibodies specificfor VCAM-J. As VCAM-1 is the endothelial cell ligand for a4:f31 integrin (VLA-4), we next tested the ability of an antibody to VCAM-1 to inhibit the pathogenesis of diabetes. Again, 2 X 107 spleen cells from diabetic NOD mice were injected into 7-8-wk-old irradiated female NOD mice with and without antibody. Antibody directed against VCAM-1 given once at the time of injection of spleen cells delayed onset of diabetes by 4 d (Fig. 3) (Fig. 4 A) . This failure to inhibit transfer of IDDM was seen even when the animals were injected three more times with antibody (Fig. 4 B) . Thus, ICAM-1 is not detectably involved in this process. The same antibody, given once, profoundly blocked transfer of EAE ( 14). Table I shows a compilation of the incidence of diabetes on day 20 in three experiments using antibodies to a4-integrin and ICAM-1. Both a4-integrin-high and a4-integrin-low-expressing T cells isolatedfrom newly diabetic NOD mice proliferate in response to NOD islets. In earlier studies of EAE, we could show no role for a4-integrin in T cell activation ( 14). However, we did observe that only a4-integrin-high T cells would respond to antigen in the EAE system. In order to control for the possibility that a4-integrin is required for the activation of islet-specific T cells in vivo, we isolated a4-integrin-high and -low-expressing populations of T cells from diabetic animals and compared their responses to NOD islets. Spleen cells were obtained from newly diabetic NOD mice, and their T cells were purified over an anti-mouse Ig column. T cells were then stained with antibody against a4-integrin and sorted according to fluorescence intensity by FACS. Cells collected were the top and bottom 10% of the fluorescence intensity curve. These cells proliferate in response to NOD islets but not NOD spleen cells, and both the a4-integrin-high and -low populations of T cells proliferate similarly (Fig. 5) . Thus, expression of high levels of a4-integrin is not required for T cell activation by islet cells.
Antibodies specific for a4-integrin and VCAM-1 affect the entry of T cells into the islets ofLangerhans. Because we have previously shown that a VLA-4-VCAM-1 interaction is crucial for the entry of T cells into brain parenchyma, and because antibodies to a4-integrin and to VCAM-1 affect the pathogenicity ofT cells that cause IDDM, we were interested to determine whether these treatments of T cells with antibodies to a4-integrin and VCAM-1 would influence their entry into the islets of Langerhans. Two mice from each of the various treatment groups in the foregoing experiments were killed on the first day that the control animals who received only spleens cells developed disease. Pancreas and spleen were removed from these animals and processed to obtain histologic sections (Fig. 6 ). Mice given spleen cells along with anti-a4-integrin one or four times showed almost no insulitis (Fig. 6, H and J) , as com- pared to mice given spleen cells only (Fig. 6 , B and E), whereas mice given spleen cells in combination with isotype matched control antibodies directed against CD45 or antibodies specific for ICAM-1 showed significant insulitis (Fig. 6, C, D , G, and I). Mice given spleen cells along with antibody specific for VCAM-1 showed slightly less insulitis than mice in the control groups, but there was still significant lymphocytic infiltrate in these mice (Fig. 6 F) . No lymphocytes were seen in the islets of control irradiated mice given no spleen cells (Fig. 6 A) . These studies show that anti-a4-integrin antibodies prevent the development of insulitis; this strongly suggests that a4-integrin on the activated T cells that produce this lesion is required for their entry into the islet. to CD4, CD8, a4-integrin, and VCAM-1. Tissue sections from control animals that received only PBS and did not develop diabetes showed no evidence of insulitis (Fig. 6 A) , and thus were negative for expression of CD4, CD8, and a4-integrin (data not shown). In addition, the islets and surrounding pancreatic tissue in such mice showed no evidence of VCAM-1 expression (data not shown). In contrast, pancreatic sections from animals that received spleen cells and developed diabetes showed infiltration by CD4 T cells, CD8 T cells, and a4-integrin-positive cells, and expressed VCAM-1 on endothelial cells (Fig. 7) . The majority of lymphocytes in the islet appear to be CD8 positive (Fig. 7 B) , but there are definitely CD4-positive T cells as well (Fig. 7 A) . As was seen in brain sections from animals with EAE ( 14), expression ofa4-integrin appears to be limited to lymphocytes surrounding small blood vessels, and those located at the outer edges of the islets (Fig. 7 C) . Expression of VCAM-1 is only seen in the islets, and it appears to be present on endothelium that has been exposed to the lymphocytic infiltrate (Fig. 7 D) . However, VCAM-1 may also be induced on other cells within the islets, such as dendritic cells. Islets contain numerous dendritic cells, as detected by staining with anti-mouse CD 1 c, but the staining pattern seen with anti-VCAM-1 is clearly distinct from the pattern seen with the antidendritic cell antibody (data not shown).
Antibody to a4-integrin or VCAM-J affects CD4 and CD8 T cell distribution in infiltrated islets. Two animals from each experimental group were also killed at the time that the first animal in that group developed diabetes. These sections were stained with antibodies specific for CD4 and CD8. Fig. 7 , A and B, shows sections from an animal that was given spleen cells alone. The islets ofLangerhans from these animals show extensive lymphocytic infiltration throughout the islets by both CD4 and CD8 T cells. (Fig. 7, G and H) . These patterns were observed for all the animals in each group that were killed at the same time (data not shown).
Discussion
The focus of the present experiments was to examine the roles of a4-integrin, VCAM-1, and ICAM-l in the pathogenesis of IDDM in the NOD mouse. Because other groups have shown that these molecules are involved in the entry of T cells into sites ofinflammation (24-28), and because we have previously shown involvement of these molecules in T cell entry into brain parenchyma ( 14), these experiments were undertaken to test the generality of the hypothesis that elevated levels of a4-integrin expressed on effector T cells interacting with VCAM-I on endothelium is involved in allowing activated T cells to leave the blood and enter normal tissue. In addition, we thought that these experiments might give some insight into The incidence of adoptive transfer of IDDM was significantly decreased by the in vivo treatment with antibodies specific for a4-integrin. Antibodies specific for ICAM-l or isotype-matched control antibodies do not significantly affect the incidence of disease.
* All animals received 2 X I07 diabetogenic NOD spleen cells. Animals were given a total of four antibody treatment.
the means by which islet-specific T cells enter the islets of Langerhans to cause IDDM. In order for autoreactive T cells to cause disease, the cells must be able to leave the blood and enter into the target tissue. In the T cell mediated autoimmune disease EAE, we have shown that the entry of an encephalitogenic CD4 T cell clone into brain parenchyma requires cell surface VLA-4 binding to endothelial cell VCAM-1, and probably lymphocyte functionassociated antigen 1 (LFA-I ) binding to ICAM-1. The current studies demonstrate a similar role for a VLA-4-VCAM-1 interaction in the pathogenesis of IDDM in the NOD mouse; and this role also appears to be in allowing entry ofCD4 T cells into One possible explanation for the effect of anti-a4-integrin antibodies is that they cause CD4 T cells to aggregate by activating a4-integrin binding. We have never observed such effects, and attempts to demonstrate homotypic adhesion induced by anti-a4-integrin antibodies failed. In addition, VCAM-1 has been suggested to be able to co-stimulate T cell growth, based on studies in which either VCAM-1 or anti-a4-integrin co-immobilized in plastic surfaces with anti-CD3 synergizes for T cell activation. However, anti-a4-integrin does not inhibit murine CD4 T cell responses ( 14) or human CD4 T cell responses to antigen, and a4-integrin-low NOD T cells respond as well to islets as a4-integrin-high T cells. Thus, we believe these alternative explanations for our results are unlikely.
The process of T cell transit across endothelium is believed to involve a cascade of events (29) (30) (31) . Many molecular pathways have been shown to participate in this process, and these pathways vary dramatically with the activation state of the interacting cells and the differentiation state ofthe T cell (32) . In addition, the various components of the cascade may differ depending on the particular type of endothelium involved. From our studies on lymphocyte entry into the central nervous system (CNS) we believe the process is initiated when activated CNS antigen-specific T-cells bind to endothelium. It has been proposed that this binding is mediated by an LFA-1-ICAM-1 interaction (33, 34) , but the initial tethering could involve selectin binding or both selectin and integrin molecules. Once the initial binding to endothelium has taken place, we believe the activated cells upregulate VCAM-1 on the endothelium by virtue of their cytokine production. The activated T lymphocyte must have surface expression of VLA-4 to bind to the newly induced VCAM-I and enter into the CNS.
The conclusion that was suggested by our earlier studies was that a VLA-4-VCAM-1 interaction is involved in the immune surveillance of tissues by activated T cells, including the CNS. We believe that a4-integrins play a role in the emigration of recently activated lymphocytes from blood into tissue. Once in the tissue, if CD4 T cells encounter specific antigen they are activated to produce cytokines that activate local endothelium to recruit further effector cells. However, it is not yet clear whether the a4-integrin-VCAM-1 interaction is required for the emigration ofthese first T cells, which we refer to as pioneer cells, from the blood into all tissues, or whether the main role for a4-integrin-VCAM-1 interaction is in the recruitment of further cells, which we refer to as settler cells, by cytokines released by these pioneer lymphocytes.
Our current studies involving T cell entry into the islets of Langerhans support this general hypothesis, but suggest that the cascade of events leading to T cell transit across endothelium may be different for CD4 and CD8 T cells, and may be different depending on the type of endothelium involved. The observation that CD4 T cells are found at the outer edges ofthe islet in animals treated with antibodies specific for a4-integrin and VCAM-1, while the CD8 cells have extensively invaded the entire islet, suggests that these antibodies preferentially block entry of CD4 T cells into tissues. What molecules regulate the migration of CD8 T cells is not clear. Although these data might be interpreted as suggesting that only CD4 T cells are crucial for fi cell destruction, they could equally support the notion that CD8 T cells require signals from proximal CD4 T cells to mediate disease.
The fact that antibodies against ICAM-1 do not appear to have the same dramatic effects in blocking IDDM as they do in blocking EAE supports the idea that the cascade ofevents leading to T cell transit across endothelium into the islets may be different from the cascade involved in T cell transit across brain endothelium. Alternatively, ICAM-1 may be acting on a population ofcells in the brain which is not necessary for onset ofdiabetes. In addition, an LFA-1 -ICAM-1 interaction may be involved in the process of T cell binding to antigen-presenting cells, and thus be involved in T cell activation. It is possible that such an interaction is necessary for antigen presentation and T cell activation in the CNS, but is not necessary in the islets of Langerhans.
Finally, in that we have previously observed spontaneous loss of a4 integrin on encephalitogenic, myelin basic proteinspecific T cells in vitro without loss of antigen specificity or lymphokine production ( 14), and inasmuch as we have also observed modulation of a4-integrin expression in vivo when cloned T cells migrate from perivascular cuffs into brain parenchyma, it is worth noting that expression of a4-integrin on T cells in the islets of Langerhans of diabetic animals appears to be limited to lymphocytes surrounding vessels, and at the outer edges of the islets. These results suggest that the regulated expression of this and other integrins may be important in effector T cell function or in migration from sites of egress from the blood to sites ofaction within the tissues themselves. The analysis of these and many other issues is crucial to understand how T cells, upon activation in the lymphoid tissues, seek out cells 
